Drug Approval | December 28, 2021
India’s 1st indigenously developed protein sub-unit Covid-19 vaccine Corbevax gets nod
It plans to deliver over 300 million doses to the Indian government
It plans to deliver over 300 million doses to the Indian government
The company will market it under the brand name Molflu
The company has developed the API in house at its R&D center in Hyderabad
The Home Healthcare market is expected to be US $ 14.2 by 2025
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Pfizer raises production projections from 80 million to 120 million courses of treatment in 2022, as a result of continued investments to support the manufacturing and distribution of Paxlovid
The VaxIT app, developed on the Salesforce platform for Azim Premji Foundation and its partners, captures the status of vaccinations to help individuals plan and stay updated on their progress
Medical footprint expansion with deeper medical grade skin contact material science expertise
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
Subscribe To Our Newsletter & Stay Updated
